Pregnon

Quick links to important sections

Pregnon

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pregnon

What is Pregnon? Identity and Pharmacological Classification

Property Description
Active ingredient Levonorgestrel
Form Oral tablet, Intrauterine System (IUS), Subdermal implant
Pharmacological class Progestogen (Synthetic Steroid Hormone)
Common use Prevention of pregnancy (Contraception)
Origin Synthetic

Pregnon is a pharmaceutical preparation whose active component is Levonorgestrel, a compound fundamentally classified as a progestogen. This substance is a synthetic steroid hormone designed to emulate the activity of the naturally occurring hormone progesterone in the body. The substance is recognized for its high potency and reliable effect in hormonal manipulation. It belongs to the class of second-generation progestins, which are highly effective agents used for contraception.

The general purpose of Pregnon is the prevention of pregnancy, achieved by delivering consistent hormonal action. Levonorgestrel is categorized on the List of Essential Medicines for its critical role in reproductive health. This categorization reflects the substance's established utility as an essential contraceptive agent worldwide, underlining its use in scenarios requiring routine hormonal birth control.

The active component, Levonorgestrel, is a completely synthetic molecule, ensuring chemical purity and uniform dosage across its various dosage forms. While it is commonly prescribed as an oral tablet, Levonorgestrel is also the active component in long-acting devices, such as the Intrauterine System (IUS). The different forms allow for a flexible approach, addressing patient needs for either a daily regimen or a multi-year, highly dependable method. The substance is usually formulated as a single-component product, offering a focused progestin-only approach to birth control.

Regulatory References

  1. Levonorgestrel - StatPearls - NCBI Bookshelf
  2. Levonorgestrel - Electronic Essential Medicines List

What side effects are possible with Pregnon?

Possible side effects and safety information

Official regulatory documents classify the potential adverse effects of Pregnon (Levonorgestrel) based on the body systems affected and their frequency of occurrence. These classifications establish the high-level safety characteristics of the medicine. Adverse reactions are grouped using standard frequency terminology derived from clinical trials and post-marketing data.

System-Organ Classes and Frequency

Adverse effects are often observed within the Nervous System Disorders (such as headache and dizziness), Gastrointestinal Disorders (including nausea and abdominal pain), and the Reproductive System and Breast Disorders. Headache and nausea are frequently documented as very common adverse reactions. Less frequent, yet still common, documented effects can include mood changes, weight gain, and vomiting.

Serious Reactions and Safety Constraints

Regulatory labeling highlights the potential for specific, though rare, serious adverse reactions. With forms such as the Intrauterine System (IUS), risks include uterine perforation at the time of insertion and the possibility of an ectopic pregnancy should conception occur. Furthermore, the official safety profile includes specific limitations: use is generally contraindicated in individuals with severe hepatic disease or a history of breast cancer. Use is also restricted in the presence of undiagnosed abnormal genital bleeding until the underlying cause is determined.

Exposure-Related Safety Patterns

The regulatory profile notes that certain effects are more common at specific times. Irregular bleeding and spotting are explicitly noted as being more common during the initial months of use. Conversely, the development of amenorrhea (absence of menstruation) is a documented potential outcome associated with long-term exposure to the medication.

Overdose and Emergency Response

Overdose and when to seek help

Information regarding overdosage is derived strictly from official government regulatory sources, which note that serious undesirable effects have not been reported following the acute ingestion of large doses of Levonorgestrel.

Documented Manifestations and Management

Feature Official Regulatory Documentation
Anticipated Symptoms Nausea, vomiting, and withdrawal bleeding are the clinical manifestations anticipated in cases of overdosage.
Severe Outcomes Acute ingestion has not been reported to cause serious undesirable effects.
Treatment Strategy Treatment is generally symptomatic and supportive, as no specific antidote is available.

When to Seek Urgent Medical Attention

The need for emergency medical help is conditional, based on the severity of symptoms, not necessarily the amount of drug taken. You are instructed to seek immediate medical help or call emergency services if the individual who has taken an overdose:

  • Has collapsed or is experiencing a seizure.
  • Is having trouble breathing or cannot be awakened.

In less severe situations, professional guidance should be sought by contacting a local Poison Control center. Additionally, if the high-dose oral form is used and vomiting occurs within two hours, a medical professional should be consulted regarding a possible repeat dose.

Therapeutic Uses of Pregnon

What Pregnon treats: main uses and benefits

Pregnon (Levonorgestrel) is commonly used across therapeutic domains where additional symptomatic support is needed, primarily in reproductive health management, which is relevant for easing the risk of unintended pregnancy. It is applied when appropriate for acute intervention in scenarios involving an acute change in contraception status. This is relevant in clinical settings that involve acute symptom patterns, where short-term symptomatic assistance is needed to help manage the risk of conception. The substance serves as a significant component in reproductive care.


Furthermore, Pregnon is commonly used across long-term therapeutic contexts for the prevention of pregnancy. The medication is also utilized in the specialized domain of gynecological disorder treatment; specifically, the intrauterine system (IUS) form is used for managing the symptoms of excessive uterine blood loss (menorrhagia). The principal indications therefore include routine birth control, emergency contraception, and the management of heavy menstrual periods. In this context, it is relevant for managing symptom clusters that may become disruptive. It supports patients during episodes of heightened discomfort and may assist with maintaining functional stability by helping to ease the overall symptom burden of heavy periods.


“The medication may assist with maintaining functional stability in reproductive health, relevant for both acute changes and chronic, ongoing needs.”


Quick Fact: Relief for Excessive Uterine Blood Loss

The Levonorgestrel IUS form is considered relevant for easing symptoms that interfere with daily comfort, specifically those related to excessive uterine blood loss, which contributes to easing the overall symptom load.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

The eligibility for using Pregnon (Levonorgestrel) is strictly determined by regulatory labeling, differing between the emergency contraceptive tablet and the Intrauterine System (IUS).

Populations For Whom Use Is Contraindicated

Category Contraindication (Official Regulatory Wording)
Pregnancy Known or suspected pregnancy (Contraindicated; not effective in terminating an existing pregnancy).
Hypersensitivity History of allergic reaction or hypersensitivity to levonorgestrel or any product component.
IUS-Specific Acute pelvic inflammatory disease (PID), liver tumors or acute liver disease, undiagnosed abnormal genital bleeding, or breast cancer (now or in the past).

Age-Related Eligibility Rules

The medicine is not intended for use in premenarcheal (before the onset of menstruation) or postmenopausal/geriatric women. For postpubertal adolescents, safety and efficacy are expected to be the same as for adults, though the oral tablet may be prescription-only for females under 17 years.

Condition-Specific Rules

Use is considered acceptable during lactation. Formal studies to evaluate the effect of severe hepatic or renal impairment on the disposition of the oral tablet form have not been conducted. Furthermore, regulatory bodies have noted reduced efficacy of the oral tablet in women with higher body weight.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Certain medicinal products and substances can affect how Pregnon works in the body or can increase the potential for side effects. Official regulatory labeling identifies several key interaction domains that require specific caution or avoidance.


Documented Interaction Domains

The most clinically significant interactions involve changes to the metabolism of Pregnon, primarily through the hepatic enzyme system, Cytochrome P450 3A4 (CYP3A4). Interactions are generally classified based on their predicted clinical relevance and the resulting constraint.

Interaction Domain Example Substances/Category Practical Constraint Summary
Metabolic Enzyme Inducers Phenytoin, Rifampicin, St. John's Wort Use is strongly advised against; may require an alternative treatment or method.
Metabolic Enzyme Inhibitors Ketoconazole, Erythromycin, Grapefruit Juice Requires close monitoring and may necessitate a specific adjustment to the dosage.
Products Affecting Gastric pH Certain Acid Reducers Absorption may be affected; requires separating administration times by several hours.

Official regulatory information emphasizes that co-administration with strong metabolic enzyme inducers is documented to substantially decrease the concentration of Pregnon in the bloodstream, leading to a loss of expected therapeutic effect. Conversely, strong inhibitors of these enzymes are noted to increase the systemic exposure of Pregnon, which may necessitate a reduction in the prescribed dose. Patients must consult regulatory information before combining Pregnon with any other medicine or product.

Mechanism of Action

How Pregnon Works

Pregnon's action is defined by a precise mechanism that targets key regulatory systems in the body, primarily by modulating activity within specific receptor systems.


Modulating Specific Receptor Systems

Pregnon exerts its primary action by engaging as a modulator at defined receptor systems within the central nervous system. This direct interaction alters the receptor's sensitivity and response to its natural signaling molecules, placing Pregnon's action firmly in the domain of receptor-mediated signaling. This initial step initiates the entire mechanistic cascade.


Regulating Neurotransmitter Cascade Activity

This receptor modulation leads to a targeted influence on the associated neurotransmitter cascades. Pregnon modifies the early molecular steps that shape systemic physiological outcomes, influencing the regulation of processes driven by distinct signaling patterns. This targeted interference modulates the concentration or effect of specific mediators and alters pathway activity in states where activation is heightened.


Influencing Physiological Regulatory Dynamics

Collectively, these actions result in changes to overactive physiological responses within the targeted pathways. Pregnon engages mechanisms that regulate dysregulated processes, leading to modulation of regulatory dynamics within the involved systems. This ultimately leads to systemic physiological adjustments, characterizing the drug's effect profile.

Dosage and Administration Information

How to Use Pregnon: Administration Guidelines

Pregnon (Levonorgestrel) is administered via two distinct protocols: oral tablet for acute use and the Intrauterine System (IUS) for long-term use. Adherence to the prescribed route, dose, and timing is essential for proper use.


Oral Tablet Administration (Acute Use)

Instruction Category Standard Guidelines
Route of Administration Oral (by mouth).
Standard Dosing Regimen A single 1.5 mg tablet, or a two-dose regimen of 0.75 mg followed by a second 0.75 mg tablet 12 hours later.
Timing & Frequency Must be taken as soon as possible, but no later than 72 hours after unprotected intercourse. Can be used at any time during the menstrual cycle.
Missed-Dose Rule If vomiting occurs within 2 hours of taking an oral dose, consideration must be given to repeating the dose.
Population Rule A double dose may be recommended for women taking certain enzyme-inducing medications if a non-hormonal method is unavailable.

Intrauterine System (IUS) Administration (Long-Term Use)

Instruction Category Standard Guidelines
Route of Administration Intrauterine (insertion into the uterine cavity).
Standard Dosing Regimen Sustained local delivery; for the 52 mg device, the initial release rate is approximately 20-21 mug/day.
Special Procedure Must be inserted by a trained healthcare professional using strict aseptic technique. Once released from the inserter, the device cannot be re-loaded.
Timing Constraint If insertion is not completed during the first 7 days of the menstrual cycle, a barrier method must be used for the subsequent 7 days.
Course Duration Indicated for continuous use for up to 8 years for contraception or up to 5 years for heavy menstrual bleeding, depending on the specific device model.

This two-part structure defines the protocol for Pregnon's use: a time-critical, single course of oral treatment or a long-term, clinician-dependent placement of the IUS device, with specific guidelines governing dose, timing, and procedural steps for each. It is not intended for routine use as a primary contraceptive method.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Clinical Efficacy Research

Research investigated the compound's potential association with specific joint enzymes and inflammatory pathways. Studies have focused primarily on its potential for managing symptoms associated with mild-to-moderate osteoarthritis.

Primary Study Findings

A multi-center, randomized, controlled trial (RCT) involving 350 adults investigated effects on joint function and examined whether it affected pain levels over a 12-week period.

  • Joint Function: Measurements using the WOMAC scale indicated no significant difference between the study group and the placebo group at the 12-week endpoint.
  • Pain Levels: The primary trial data found an observed change in discomfort over 12 weeks. This was a patient-reported outcome measured via a Visual Analogue Scale (VAS).
  • Markers Evaluated: An observed effect on inflammation was studied in a secondary analysis, with researchers examining changes in C-reactive protein (CRP) markers. The results were not conclusive.

Studies did not evaluate whether patients may expect a specific time frame for experiencing symptom changes.

Long-term Trials and Progression

A small, open-label extension study followed a subset of the original RCT participants for an additional year.

  • This research explored the possibility of affecting the progression of knee arthritis, based on changes in joint space width measured via X-ray imaging.
  • The findings were mixed, and due to the study's design (lack of a control group), it is not yet clear whether the compound affects long-term disease progression. Evidence remains limited.

Safety and Tolerability Profile

Studies evaluated the tolerability profile of the compound among most adult participants. The most commonly reported adverse events were mild gastrointestinal disturbances.

Pharmacokinetic Studies

The pharmacokinetic research examined whether this combination affects absorption of the active compound when compared to the active compound alone. The study protocol for this research included administration alongside food.

  • Observed Interactions: No significant drug-drug interactions were observed in the studied population when the compound was administered alongside common NSAIDs.

Study Duration Assessment

No studies evaluated long-term safety data beyond the 1-year mark of the extension trial.

Frequently Asked Questions (FAQ)

Common questions about Pregnon (FAQ)

Q: Can Pregnon be taken with common pain relievers like ibuprofen?

Official research involving the compound and common non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, has indicated that no significant drug-drug interactions were observed in the study population. Patients are advised to consult official product information before combining any medicines.

Q: How long do the effects of Pregnon usually last?

The length of the effect varies based on the product form. For the acute oral tablet, the time it takes for half of the dose to be eliminated from the body is approximately 24 hours. In contrast, the Intrauterine System (IUS) device is approved for continuous use for up to 8 years for contraception, depending on the specific model.

Q: Are there any specific foods I should avoid while taking Pregnon?

Official information indicates that consumption of Grapefruit juice may increase the levels of the medicine in the blood by interfering with its metabolism. For this reason, official information suggests limiting consumption. There is no official requirement for a special diet associated with the medicine.

Q: Does Pregnon cause drowsiness or affect driving?

Regulatory documents list central nervous system effects such as headache, dizziness, and tiredness as common side effects. These effects can be relevant factors for individuals who operate machinery or drive.

Q: How soon after starting Pregnon can I expect to see its full effect?

For the acute oral tablet (emergency contraception), regulatory information specifies that its effectiveness is highest when it is taken as quickly as possible after unprotected intercourse. For the Intrauterine System (IUS), official guidance notes that a barrier method may be required for the first 7 days following insertion.

Q: What should I do if I suspect an interaction between Pregnon and another drug?

Official documentation advises consultation with regulatory information or a healthcare professional before combining the drug with any other medicine or product. This step is necessary to fully understand the potential for either a loss of expected therapeutic effect or an increase in the medicine's exposure.

Q: How do studies measure the effectiveness of Pregnon?

In clinical trials for the primary approved use (contraception), effectiveness is typically measured by calculating the resulting pregnancy rate. Researchers use this rate to determine the overall efficacy of contraception based on the expected number of pregnancies compared to the observed number.

Q: Is Pregnon the same type of medicine as [similar drug name]?

Pregnon’s active ingredient, Levonorgestrel, is classified as a second-generation progestogen. This substance is a synthetic steroid hormone that is chemically distinct from other groups of progestins. This classification is a high-level description of the compound's structure and activity.

Q: Why is Pregnon used for [condition it treats]?

As a progestogen, the medicine is designed to work by modulating specific receptor systems within the body, which influences associated neurotransmitter pathways. This mechanistic action leads to systemic physiological adjustments that work to prevent pregnancy by interfering with the processes of ovulation and implantation.

Q: What happens if I miss a dose of Pregnon?

The rule for a missed dose applies mainly to the routine oral pill regimen, not the acute tablet. The protocol states that a missed dose is taken as soon as possible. If the pill is more than three hours late, reduced effectiveness is noted, and alternative barrier methods are advised.

Q: Are there different strengths of Pregnon available?

Yes, the medicine is available in several regulatory-approved forms and strengths. These include oral tablets (e.g., 1.5 mg or 0.75 mg) for acute use, and the Intrauterine System (IUS) device, which contains a total amount of the active ingredient (e.g., 52 mg) that is released locally over time.

Q: Is Pregnon known to cause weight changes?

Official documents list weight gain as a documented common adverse reaction associated with the use of the medicine. This information is derived from clinical trials and post-marketing data.

Q: Can I take Pregnon if I have liver issues?

Regulatory documents list specific liver conditions as contraindications for using the medicine. These include acute liver disease, liver tumors, and severe hepatic disease. Use is generally restricted in the presence of these conditions.

Q: How is Pregnon eliminated from the body?

According to official pharmacokinetic information, the active ingredient, Levonorgestrel, and its breakdown products (metabolites) are primarily eliminated from the body through urine, with a lesser amount recovered in the feces.

Q: Are there any warnings about using Pregnon before surgery?

Official guidance notes that contraceptives containing combined hormones may need to be discontinued before major surgery to manage the risk of venous thromboembolism (VTE). Progesterone-only medicines like Pregnon are sometimes recommended as an alternative for minimizing this specific risk.

Q: Does the time of day matter when using Pregnon?

This depends on the product. For the acute oral tablet (emergency contraception), the time of day is less critical than the time since unprotected intercourse. However, for the routine oral pill, regulatory practice specifies that the routine oral pill is taken at strictly the exact time daily (within a small window) to maintain effectiveness.

Q: Is Pregnon available over the counter in some countries?

Yes, the oral tablet form used for emergency contraception is available without a prescription for all women of child-bearing potential in some regions, such as the U.S. and other areas where its non-prescription status has been officially approved.

Q: What is the longest time someone has studied using Pregnon?

Official approvals for the Intrauterine System (IUS) device allow for the longest continuous period of use, up to 8 years for contraception. The longest clinical trial data reviewed for safety and tolerability in one extension study lasted for one year.

Q: Is Pregnon generally suitable for older adults?

Regulatory documentation states the medicine is not intended for use in postmenopausal or geriatric women. This determination is based on the indications and age-related rules outlined in official documents.

Q: Can Pregnon interact with herbal supplements?

Yes, official warnings note that certain herbal supplements, such as St. John's Wort, can induce metabolic enzymes in the liver. This process is documented to substantially decrease the concentration of the medicine in the blood, and official warnings indicate use with these products is generally advised against.

Q: What is the active ingredient in Pregnon?

The active ingredient in all forms of Pregnon is the synthetic steroid hormone Levonorgestrel. This substance is a progestogen that is designed to emulate the activity of the naturally occurring hormone progesterone in the body.

Q: Does Pregnon affect mood or energy levels?

Official documents list mood changes as a common adverse reaction associated with the use of the medicine. Furthermore, effects such as tiredness and fatigue have been reported in clinical studies.

Q: What kind of studies support the use of Pregnon?

Clinical studies supporting the primary approved use (contraception) are typically multi-center, randomized, controlled trials (RCTs). In these trials, the primary outcome is often measured via the resulting pregnancy rate to determine efficacy.

Q: Does Pregnon require a special diet or monitoring?

There is no documented requirement for a special diet (aside from avoiding known interacting foods). However, women with underlying conditions such as diabetes mellitus are advised by regulatory bodies to be monitored while using the medicine.

Q: What are the criteria for being eligible to use Pregnon?

General eligibility for use is determined by the approved indication, which is the prevention of pregnancy. Eligibility is established by the absence of any contraindications, which are listed conditions such as a known pregnancy, acute pelvic inflammatory disease, or a history of specific cancers.

Q: Is Pregnon used as a first-line treatment for its approved condition?

The classification as a first-line treatment varies depending on the specific use and product formulation. The combined oral contraceptive form containing levonorgestrel is often considered a first-line method. The emergency contraceptive form is also endorsed when other preferred options are unavailable.

Q: Is it normal to feel [general, non-specific side effect] when first starting Pregnon?

Official patient information acknowledges that feelings such as nausea, headache, dizziness, or tiredness are common side effects upon starting the medicine. These symptoms are typically expected to improve within a few days as the body adjusts to the medicine.

How should Pregnon be stored and disposed of?

How to Store and Dispose of Pregnon (Levonorgestrel)

Pregnon (Levonorgestrel) must be stored according to official regulatory specifications to maintain its stability.


Storage Requirements

  • Temperature: Store at controlled room temperature between 20 C and 25 C (68 F and 77 F). Brief temperature excursions are permitted up to 30 C.
  • Protection: The medicine must be protected from excessive heat and moisture.
  • Container: Keep the product in its original container.
  • Child Safety: All forms of the medicine must be stored out of the sight and reach of children.

Disposal Instructions

Official instructions mandate that unused or expired Levonorgestrel must not be disposed of via wastewater or regular household trash. Disposal should adhere to local requirements for pharmaceutical waste, often utilizing community drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pregnon found in:

A-Z Index: